Talimogene laherparepvec

Drug Profile

Talimogene laherparepvec

Alternative Names: Herpes simplex virus type 1 GM CSF vaccine; IMLYGIC; JS1/34.5- /47-/GM-CSF; JS1/34.5- /47-/GM-CSF vaccine; OncoVEXGM-CSF; T-VEC

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex; M. D. Anderson Cancer Center; Merck & Co; University of Iowa
  • Class Gene therapies; Oncolytic viruses
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Soft tissue sarcoma
  • Phase I Head and neck cancer; Liver cancer
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Soft tissue sarcoma (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (Intratumoural) (NCT03069378)
  • 01 Mar 2017 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease) in Japan (Intratumoural) (NCT03064763)
  • 07 Oct 2016 Interim efficacy and adverse events data from phase II part of the phase I/II trial in Malignant melanoma (Combination therapy, First-line therapy, Inoperable/Unresectable) presented at the 41st Congress of the European Society for Medical Oncology (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top